David A. Scheinberg

Weill Cornell Medical College, New York, NY, United States 
"David Scheinberg"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Dao T, Klatt MG, Korontsvit T, et al. (2020) Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunology, Immunotherapy : Cii
Cheal SM, McDevitt MR, Santich BH, et al. (2020) Alpha radioimmunotherapy using Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 10: 11359-11375
Krebs S, Dacek MM, Carter LM, et al. (2020) CAR Chase: Where Do Engineered Cells Go in Humans? Frontiers in Oncology. 10: 577773
Klatt MG, Mack KN, Bai Y, et al. (2020) Solving an MHC allele specific bias in the reported immunopeptidome. Jci Insight
Gejman RS, Jones HF, Klatt MG, et al. (2020) Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunology Research
Urbanska AM, Khanin R, Alidori S, et al. (2020) A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles. Cancer Biotherapy & Radiopharmaceuticals
Mondello P, Tadros S, Teater M, et al. (2020) Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery
Oh CY, Klatt MG, Bourne C, et al. (2019) ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome. Cancer Immunology Research
Dao T, Mun SS, Scott AC, et al. (2019) Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. Oncoimmunology. 8: 1570778
Gejman RS, Chang AY, Jones HF, et al. (2018) Rejection of immunogenic tumor clones is limited by clonal fraction. Elife. 7
See more...